

Contents

Subject	Page
List of tables	I
List of figures	I
List of abbreviations	I-I
Abstract	I
Introduction	1-2
Aim Of The Work	3
Review Of Literature	4-45
Hepatitis C viral infection	4-18
Causative agent and virology	4-5
Historical review	6
Geographical pattern	6-7
HCV in Egypt	8-9
Mode of transmission	9-12
Chronic HCV infection	13
Diagnosis	14-17
HCV Genotyping	18
Treatment of HCV Infection	19-28
The Optimal Treatment of Chronic HCV	24-26
Effects of Higher Doses and Extended Duration of Treatment.	26-28
Side effects of interferon and ribavirin	29-36
The most common side effects	29-30
Hematological side effects	31-36
Management of hematological side effects	37-45
Management of anemia	37-40
Management of Neutropenia	41-43
Management of Thrombocytopenia	44-45
Patients and Methods	46-50
Results	51-96
Discussion	97-109
Summary	110-112
Conclusion	113-114
Recommendations	115
References	116-133
Arabic summary	1-6

List of tables

Table NO	Title	Page NO
Table 1	Hepatitis C estimated prevalence and number infected by WHO RegionWHO,1999	6
Table 2	Percentage of male and female in studied cases	51
Table 3	Percentage of diabetics and non diabetics in studied case	51
Table 4	characteristics in studied case	52
Table 5	Percentage of fibrosis stage in studied case	53
Table 6	Percentage of activity stage in studied case	54
Table 7	Response of group 1 all over weeks	55
Table 8	Response of group 2all over weeks	56
Table 9	response of both groups all over the weeks of therapy	58
Table 10	Mean hemoglobin changes during 48 weeks of therapy in group 1	59
Table 11	Incidence of developing mild ,moderate and severe anemia in group 1	60
Table 12	Mean hemoglobin changes during 48 weeks of therapy in group 2	62
Table 13	Incidence of developing mild ,moderate and severe anemia in group 2	63
Table 14	Mean neutrophilic count changes during 48 weeks of therapy in group 1	65
Table 15	Incidence of developing mild ,moderate and severe neutropenia in group 1	66
Table 16	Mean neutrophilic count changes during 48 weeks of therapy in group 2	68
Table 17	Incidence of developing mild ,moderate and severe neutropenia in group 2	69
Table 18	Mean platelets count changes during 48 weeks of therapy in group 1	71
Table 19	Incidence of developing mild ,moderate and severe thrombocytopenia in group 1	72
Table 20	Mean platelets count changes during 48 weeks of therapy in group 2	74
Table 21	Incidence of developing mild ,moderate and severe thrombocytopenia in group 2	75
Table 22	EVR according to different Ribavirin dose in group 1	77
Table 23	EVR according to different Ribavirin dose in group 2	78
Table 24	Late virological response according to different Ribavirin dose in group 1	79
Table 25	Late virological response according to different Ribavirin dose in group 2	80
Table 26	ETR according to different Ribavirin dose in group 1	81
Table 27	ETR according to different Ribavirin dose in group 2	82
Table 28	SVR according to different Ribavirin dose in group 1	83
Table 29	SVR according to different Ribavirin dose in group 2	84
Table 30	EVR according to different PEG –interferon dose in group 1	87
Table 31	EVR according to different PEG –interferon dose in group 2	88
Table 32	Late virological response according to different PEG –interferon dose in group 1	89
Table 33	Late virological response according to different PEG –interferon dose in group 2	90
Table 34	ETR according to different PEG –interferon dose in group 1	91
Table 35	ETR according to different PEG –interferon dose in group 2	92
Table 36	SVR according to different PEG –interferon dose in group 1	93
Table 37	SVR according to different PEG –interferon dose in group 2	94

List of figures

Figure NO	Title	Page NO
Figure 1	Graphic display of virological responses.	7
Figure 2	Percentage of male and female in studied case	23
Figure 3	Percentage of diabetics and non diabetics in studied case	51
Figure 4	Percentage of fibrosis stage in studied case	52
Figure 5	Percentage of activity stage in studied case	53
Figure 6	Response of both groups all over the weeks of therapy	54
Figure 7	Mean hemoglobin changes during 48 weeks of therapy in group 1	58
Figure 8	Incidence of developing mild ,moderate and severe anemia in group 1	60
Figure 9	Mean hemoglobin changes during 48 weeks of therapy in group 2	61
Figure 10	Incidence of developing mild ,moderate and severe anemia in group 2	63
Figure 11	Mean neutrophilic count changes during 48 weeks of therapy in group 1	64
Figure 12	Incidence of developing mild ,moderate and severe neutropenia in group 1	66
Figure 13	Mean neutrophilic count changes during 48 weeks of therapy in group 2	67
Figure 14	Incidence of developing mild ,moderate and severe neutropenia in group 2	69
Figure 15	Mean platelets count changes during 48 weeks of therapy in group 1	70
Figure 16	Incidence of developing mild ,moderate and severe thrombocytopenia in group 1	72
Figure 17	Mean platelets count changes during 48 weeks of therapy in group 2	73
Figure 18	Incidence of developing mild ,moderate and severe thrombocytopenia in group 2	75
Figure 19	Effect of cumulative ribavirin dose exposure as an impact of anemia on different type of response in group 1	76
Figure 20	Effect of cumulative ribavirin dose exposure as an impact of anemia on different type of response in group 2	85
Figure 21	Effect of cumulative interferon dose exposure as an impact of neutropenia and thrombocytopenia on different type of response in group 1	86
Figure 22	Effect of cumulative interferon dose exposure as an impact of neutropenia and thrombocytopenia on different type of response in group 2	96

List of abbreviations

AFP	Alpha- fetoprotein
ALB	Albumin
AlkPh	Alkaline phosphatase
ALT	Alanine transaminase
ANC	Absolute neutrophilic count
AST	Aspartate transaminase
BMI	Body mass index
CDC	Centers for Disease Control and Prevention
Creat	Creatinine
EIA	Enzyme immunoassay
ELISA	Enzyme linked immunosorbent assay
EVR	Early virological response
ETR	End treatment response
Hb	Hemoglobin
HAV	Hepatitis A virus
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
HVR	Hyper variable regions
IFN therapy	Interferon therapy
IgG	Immunoglobulin G
IgM	Immunoglobulin M
MOHP	Ministry of Health and Population
NIH	National Institutes of Health
NLI	National Liver Institute
Plt	Platelets
PT	Prothrombine time

RIBA	Recombinant immunoblot assay
RBV	Ribavirin
RT-PCR	Reverse transcription polymerase chain reaction.
SD	Standard deviation.
SVR	Sustained Virological Response
T.Bil	Total bilirubin
TMA	Transcription- mediated amplification
WBC	white blood cells
Wt	weight
X²	Chi-square test

Abstract

Introduction: Pegylated interferon and ribavirin combination therapy currently represents the standard of care for the treatment of chronic hepatitis C infection. Hematological side effects of pegylated interferon and ribavirin occur frequently and limit adherence to therapy and, ultimately, treatment efficacy.

Aim: the study of the hematological side effects of peg interferon and ribavirin and its impact on the virological responses.

Methods: 1080 Adult patients with chronic hepatitis C who were treated with Peg-IFN α -2b at a dose of 1.5 μ g/kg or Peg-IFN α -2a at a dose of 180 μ g/week plus a ribavirin dose of 1,000-1,200 mg/day, according to weight.

Results : Anemia occurred in about 52.2% of the studied patients as the following : mild anemia (Hb<12 gm/dl) in 27.4% , moderate anemia (Hb<10 gm/dl) in 15.7% and severe anemia (Hb<8.5 gm/dl) in 9.1% and this led to ribavirin dose modification in about 15.7% of patients and its stoppage occurred in about 9.1% of patients.

Neutropenia was also a common side effect which occurred in about 45.6% of the studied patients as the following : mild neutropenia (ANC<1500/ μ L) in 31.2% , moderate neutropenia (ANC<750/ μ L) in 19.8% and severe neutropenia (ANC<500/ μ L) in 4.7% and this led to interferon dose modification in about 19.8% of patients and its stoppage in about 4.7% of patients.

Thrombocytopenia occurred in about 40.7% of the studied patients as the following : mild thrombocytopenia (platelets<150000/ μ L) in 35.8% , moderate thrombocytopenia (platelets <50000/ μ L) in 3.6% and severe thrombocytopenia (platelets <25000/ μ L) in 1.3% and this led to interferon dose modification in about 3.6% of patients and its stoppage in about 1.3% of patients.

Modification of Ribavirin dose was associated with decrease in response all over the weeks of therapy and it appeared more profound when this modification led to Ribavirin dose to fall below 70% of recommended dose or when this modification had occurred in the first 24 weeks even to lesser extent.

Conclusions: Adherence to treatment is important to optimize the desirable SVR and reduction of the dose of either peg interferon or Ribavirin in first 12 weeks of therapy sharply lowered the EVR and so SVR , also reduction of the total dose to less than 70% is associated with a sharp fall in SVR .